跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

46531

Supelco

新生霉素 钠盐

VETRANAL®, analytical standard

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C31H35N2NaO11
CAS號碼:
1476-53-5
分子量：:
634.61
Beilstein:
3892910
EC號碼:
216-023-6
MDL號碼:
MFCD07636891
分類程式碼代碼:
41116107
PubChem物質ID:
24870266
NACRES:
NA.24

等級

analytical standard

品質等級

100

產品線

VETRANAL®

化驗

97.9% (HPLC)

儲存期限

limited shelf life, expiry date on the label

技術

HPLC: suitable
gas chromatography (GC): suitable

抗生素活性譜

Gram-positive bacteria

應用

clinical testing

形式

neat

作用方式

DNA synthesis | interferes
enzyme | inhibits

儲存溫度

2-8°C

SMILES 字串

[Na+].CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3C([O-])=C(NC(=O)c4ccc(O)c(C\C=C(\C)C)c4)C(=O)Oc3c2C)OC1(C)C

InChI

1S/C31H35N2O11.Na/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29;/h7,9-13,23,25-26,29,34,36H,8H2,1-6H3,(H2,32,39)(H,33,37);/q-1;+1

InChI 密鑰

AXOUUAINTJNFRS-UHFFFAOYSA-N

尋找類似的產品？ 前往 產品比較指南

相關類別

一般說明

Chemical structure: coumarin-glycoside

應用

For the production of positively supercoiled plasmid DNA. Inhibitor of bacterial DNA gyrase and eukaryotic DNA topoisomerase. Inhibitor of retrovirus RNA-dependent DNA-polymerase.
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

生化／生理作用

Mode of Action: Inhibits DNA synthesis by inhibiting the enzyme Topoisomerase II.
Antimicrobial spectrum: Gram-positive bacterial.

法律資訊

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

象形圖

Exclamation mark
GHS07

訊號詞

Warning

危險聲明

H302,H317,H319

危險分類

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Sens. 1

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 1

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number
BCCK2243
BCCB6920

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Jeffery D Eskew et al.
BMC cancer, 11, 468-468 (2011-11-02)
The molecular chaperone, heat shock protein 90 (Hsp90) has been shown to be overexpressed in a number of cancers, including prostate cancer, making it an important target for drug discovery. Unfortunately, results with N-terminal inhibitors from initial clinical trials have
Huiping Zhao et al.
Bioorganic & medicinal chemistry letters, 23(2), 552-557 (2012-12-14)
Hsp90 is a promising therapeutic target for the treatment of cancer. Novobiocin is the first Hsp90 C-terminal inhibitor ever identified and recent structure-activity relationship studies on the noviose sugar identified several commercially available amines as suitable surrogates. In an effort
Bhaskar Reddy Kusuma et al.
Bioorganic & medicinal chemistry letters, 21(23), 7170-7174 (2011-10-22)
Novobiocin analogs lacking labile glycosidic ether have been designed, synthesized and evaluated for Hsp90 inhibitory activity. Replacement of the synthetically complex noviose sugar with simple aromatic side chains produced analogs that maintain moderate cytotoxic activity against MCF7 and SkBR3 breast
Sidharth Chopra et al.
The Journal of antimicrobial chemotherapy, 67(2), 415-421 (2011-11-05)
New classes of drugs are needed to treat tuberculosis (TB) in order to combat the emergence of resistance to existing agents and shorten the duration of therapy. Targeting DNA gyrase is a clinically validated therapeutic approach using fluoroquinolone antibiotics to
Roman Pantůček et al.
Systematic and applied microbiology, 36(2), 90-95 (2013-01-16)
Thirteen coagulase-negative, oxidase-negative, and novobiocin-susceptible staphylococci were isolated from human clinical specimens. The isolates were differentiated from known staphylococcal species on the basis of 16S rRNA, hsp60, rpoB, dnaJ, tuf, and gap gene sequencing, automated ribotyping, (GTG)5-PCR fingerprinting, and MALDI-TOF
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務